Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.68 |
| ▸ | PIK3R2 | O00459 | 13/20 | 0.68 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.68 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.53 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19322377 | 0.93 | PIK3CD (0.69) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| SCHEMBL19322378 | 0.90 | PIK3CD (0.69) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| SCHEMBL19322349 | 0.89 | PIK3CD (0.69) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| SCHEMBL19322361 | 0.87 | PIK3CD (0.66) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| SCHEMBL19322416 | 0.86 | PIK3CD (0.71) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| SCHEMBL19322411 | 0.86 | PIK3CD (0.68) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| SCHEMBL19322389 | 0.85 | PIK3CD (0.69) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| SCHEMBL19322412 | 0.85 | PIK3CD (0.69) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| SCHEMBL19322348 | 0.83 | PIK3CD (0.68) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| SCHEMBL19322351 | 0.83 | PIK3CD (0.67) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208066-B2 | Imidazopyridazine compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-02-19 | — | — | US | disclosed |
| US-20170253618-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253618-A1 | NOVEL IMIDAZOPYRIDAZINE COMPOUNDS AND THEIR USE | PIK3R5, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3R2 10/4885PIK3CG 9/4885 |
| US-10208066-B2 | Imidazopyridazine compounds and their use | PIK3R5, PIK3CD, INPP5D | PIK3CD 2/4885PIK3R2 9/4885PIK3CG 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.